About Us

Ankasa is developing ART352-L as a novel regenerative medicine. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.

Ankasa’s lead indication is augmentation of autograft used in spinal fusion for treatment of degenerative changes in intervertebral discs, a highly prevalent chronic, debilitating condition that can severely impact day-to-day functioning. Our preclinical data suggest that treatment of a patient’s autograft with ART352-L will generate significantly more bone without unwanted bone overgrowth, thus reducing the rate of revision surgeries and their attendant complications. This is a direct benefit to the target patient population as well as a direct savings to the healthcare system.

Ankasa has raised over $19M from a venture investment syndicate, led by Avalon Ventures and including Heraeus Medical GmbH, Correlation Ventures and Stanford University. We have also been awarded over $6M from The California Institute of Regenerative Medicine (CIRM) in two grants to support pre-clinical research and our Investigational New Drug (IND) submission.

About Us

Ankasa is developing ART352-L as a novel regenerative medicine. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.

Ankasa’s lead indication is augmentation of autograft used in spinal fusion for treatment of degenerative changes in intervertebral discs, a highly prevalent chronic, debilitating condition that can severely impact day-to-day functioning. Our preclinical data suggest that treatment of a patient’s autograft with ART352-L will generate significantly more bone without unwanted bone overgrowth, thus reducing the rate of revision surgeries and their attendant complications. This is a direct benefit to the target patient population as well as a direct savings to the healthcare system.

Ankasa has raised over $19M from a venture investment syndicate, led by Avalon Ventures and including Heraeus Medical GmbH, Correlation Ventures and Stanford University. We have also been awarded over $6M from The California Institute of Regenerative Medicine (CIRM) in two grants to support pre-clinical research and our Investigational New Drug (IND) submission.

Ankasa’s mission is to provide a better quality of life for patients undergoing surgical bone reconstruction procedures by offering faster healing, improved bone growth and reduction in pain and revisions surgeries.

Management Team & Key People

Sanford J. Madigan, Ph.D.

Co-Founder, Chief Executive Officer

Gloria Matthews, DVM, Ph.D., DACVS

Chief Medical Officer

Jill Helms, D.D.S., Ph.D.

Co-Founder, Senior Advisor

Scientific Advisory Board

David Lacey, M.D.

Co-Founder, Chair SAB

Roland Baron, D.D.S., Ph.D.

Professor and Chair, Department of Oral Medicine
Harvard School of Dental Medicine

Phillip Leucht, M.D.

Associate Professor, Department of Orthopaedic Surgery
Associate Professor, Department of Cell Biology
NYU Langone Health, Langone Orthopedic Hospital

© 2019 Ankasa. All Rights Reserved